| Literature DB >> 32270710 |
Alexandra S Zimmer1, Seth M Steinberg2, Dee Dee Smart3, Mark R Gilbert4, Terri S Armstrong4, Eric Burton4, Nicole Houston1, Nadia Biassou5, Brunilde Gril1, Priscilla K Brastianos6, Scott Carter7, David Lyden8, Stanley Lipkowitz1, Patricia S Steeg1.
Abstract
Brain metastases occur in up to 25-55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood-brain barrier and is US FDA approved for treatment of glioblastoma. Our group has demonstrated that low doses of TMZ administered in a prophylactic, metronomic fashion can significantly prevent development of brain metastases in murine models of breast cancer. Based on these findings, we initiated a secondary-prevention clinical trial with oral TMZ given to HER2-positive breast cancer patients with brain metastases after recent local treatment in combination with T-DM1 for systemic control of disease. Primary end point is freedom from new brain metastases at 1 year. (NCT03190967).Entities:
Keywords: T-DM1; brain metastases; metastatic breast cancer; secondary prevention; temozolomide
Mesh：
Substances：
Year: 2020 PMID： 32270710 PMCID： PMC7270957 DOI： 10.2217/fon-2020-0094
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404